Chronic use of saracatinib as a SRC family inhibitor was recently explored in 2 phase II clinical studies in Alzheimer’s disease and lymphangioleiomyomatosis (ClinicalTrials.gov identifiers NCT02167256 and NCT02737202, respectively). Here, SRC is linked to early-onset autosomal dominant Alzheimer disease.